GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » DARA Biosciences Inc (NAS:DARA) » Definitions » Depreciation, Depletion and Amortization

DARA Biosciences (DARA Biosciences) Depreciation, Depletion and Amortization : $0.68 Mil (TTM As of Sep. 2015)


View and export this data going back to . Start your Free Trial

What is DARA Biosciences Depreciation, Depletion and Amortization?

DARA Biosciences's depreciation, depletion and amortization for the three months ended in Sep. 2015 was $0.17 Mil. Its depreciation, depletion and amortization for the trailing twelve months (TTM) ended in Sep. 2015 was $0.68 Mil.


DARA Biosciences Depreciation, Depletion and Amortization Historical Data

The historical data trend for DARA Biosciences's Depreciation, Depletion and Amortization can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DARA Biosciences Depreciation, Depletion and Amortization Chart

DARA Biosciences Annual Data
Trend Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14
Depreciation, Depletion and Amortization
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.15 0.14 0.66 0.63 0.64

DARA Biosciences Quarterly Data
Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15
Depreciation, Depletion and Amortization Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.16 0.16 0.18 0.17 0.17

DARA Biosciences Depreciation, Depletion and Amortization Calculation

Depreciation is a present expense that accounts for the past cost of an asset that is now providing benefits.

Depletion and amortization are synonyms for depreciation.

Generally:
The term depreciation is used when discussing man made tangible assets
The term depletion is used when discussing natural tangible assets
The term amortization is used when discussing intangible assets

Depreciation, Depletion and Amortization for the trailing twelve months (TTM) ended in Sep. 2015 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.68 Mil.


* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


DARA Biosciences  (NAS:DARA) Depreciation, Depletion and Amortization Explanation

One of the key tenets of Generally Accepted Accounting Principles (GAAP) is the matching principle. The matching principle states that companies should report associated costs and benefits at the same time.

For example:

If a company buys a $300 million cruise ship in 1982 and then sells tickets to passengers for the next 30 years, the company should not report a $300 million expense in 1982 and then ticket sales for 1982 through 2012. Instead, the company should spread the purchase price of the ship (the cost) over the same time period it sells tickets (the benefit).

To create income statements that meet the matching principle, accountants use an expense called depreciation.

So, instead of reporting a $300 million purchase expense in 1982, the company might:

Report a $30 million depreciation expense in 1982, 1983, 1984...and every year after that for the 30 years the company expects to sell tickets to passengers on this cruise ship.

To calculate depreciation, a company must make estimates and choices such as:

The cost of the asset
The useful life of the asset
The salvage value of the asset at the end of its useful life
And a way of spreading the cost of the asset to match the time when the asset provides benefits

The range of different ways of spreading the cost under GAAP accounting is too long to list. However, public companies in the United States explain their depreciation choices to shareholders in a note to their financial statements. It is critical that investors read this note. Investors can find this note in the company's 10-K.

Past depreciation expenses accumulate on the balance sheet. Most public companies choose not to show this contra asset account on the balance sheet they present to shareholders. Instead, they simply show a single item. This single asset item may be marked Net. Such as Property, Plant, and Equipment - Net. It is actually the asset account netted against the contra asset account.

A contra asset account is an account that offsets an asset account. So, for example a company might have:

Property, Plant, and Equipment - Gross: $150 million
Accumulated Depreciation: $120 million
Property, Plant, and Equipment - Net: $30 million

In this case, the only item likely to be shown on the balance sheet is Property, Plant, and Equipment - Net. This is the cost of the company's property, plant, and equipment (asset account) minus the accumulated depreciation (the contra asset account). It means the company's assets cost $150 million, the company has reported $120 million in depreciation expense over the years, and the company is now reporting the assets have a book value of $30 million.

It is possible for a company to have fully depreciated assets on its balance sheet. This means the company's estimate of the useful life of the asset was shorter than the asset's actual useful life. As a result, the asset - although it is still being used - is carried on the balance sheet at its salvage value.

This is a reminder that depreciation involves estimates and choices. It is not an infallible process.

Companies do not have cash layout for depreciation. Therefore, depreciation is added back in the cash flow statement.

Although depreciation is not a cash cost, it is a real business cost because the company has to pay for the fixed assets when it purchases them. Both Warren Buffett and Charlie Munger hate the idea of EDITDA because depreciation is not included as an expense. Warren Buffett even jokingly said We prefer earnings before everything when criticizing the abuse of EDITDA.


Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.


DARA Biosciences Depreciation, Depletion and Amortization Related Terms

Thank you for viewing the detailed overview of DARA Biosciences's Depreciation, Depletion and Amortization provided by GuruFocus.com. Please click on the following links to see related term pages.


DARA Biosciences (DARA Biosciences) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » DARA Biosciences Inc (NAS:DARA) » Definitions » Depreciation, Depletion and Amortization
Traded in Other Exchanges
N/A
Address
DARA Biosciences Inc was incorporated on June 22, 2002. It is a specialty pharmaceutical company focused on the development and commercialization of oncology treatment and supportive care pharmaceutical products. Through its acquisition of Oncogenerix, Inc., which occurred on January 17, 2012, the Company acquired exclusive U.S. marketing rights to its first commercial proprietary product, Soltamox (oral liquid tamoxifen). The Company's main focus is on the development and commercialization of oncology treatment and supportive care pharmaceutical products: Soltamox, Gemcitabine and other generic sterile injectable cytotoxic products, and Cancer support therapeutics. Soltamox (oral liquid tamoxifen), its first proprietary, FDA approved product, is a drug primarily used to treat breast cancer. Soltamox has been approved by the U.S. Food and Drug Administration ('FDA') for the treatment of breast cancer. Soltamox will be the only liquid formulation of tamoxifen available for sale in the United States. Soltamox is used mainly for the chronic treatment of breast cancer or for cancer prevention in certain susceptible breast cancer subgroups. The Company is also focusing on the development and commercialization of generic sterile injectable cytotoxic products. The Company's agreement with Uman Pharma Inc. pursuant to which it received an exclusive license to import, sell, market and distribute Uman's gemcitabine lyophilized powder product in 200mg and 1g dosage sizes in the U.S. Gemcitabine went off patent in 2011 in the U.S. and is prescribed as first-line therapy for ovarian, breast, lung and pancreatic cancers. Currently, the Company has two main drug candidates advancing through clinical development with cleared Investigational New Drug applications from the FDA: KRN5500, a novel, non-narcotic/non-opioid for the treatment of neuropathic pain in patients with cancer; and DB959, a first-in-class drug candidate for the treatment of type 2 diabetes and dyslipidemia. The Company mainly competes with other pharmaceutical companies, biotechnology companies and other research and academic institutions. The Company's advertising, marketing and distribution of pharmaceutical products in the United States is subject to the regulation of United States Food, Drug and Cosmetic Act.
Executives
David Drutz director, officer: Executive Chairman and CMO 8601 SIX FORKS ROAD, SUITE 160, RALEIGH NC 27615
David L. Tousley officer: CFO 14610 PAWNEE LANE, LEAWOOD KS 66224
Gail Lieberman director 175 EAST 79TH STREET, APT. 4D, NEW YORK NY 10075
Paul John Richardson director 17 COUNTRY OAKS ROAD, LEBANON NJ 08833
Steve Gorlin director 150 GULF SHORE DRIVE, UNIT 601, DESTIN FL 32541
Ann A Rosar officer: Vice President Finance C/O 801 CAPITOLA DRIVE, DURHAM NC 27713
John C Thomas director 8601 SIX FORKS ROAD, SUITE 160, RALEIGH NC 27615
Geert Cauwenbergh director 1 STULTS DRIVE, PLAINSBORO NJ 08536
Kurt M Eichler director C/O SPRING BANK PHARMACEUTICALS, INC., STE S-7, MILFORD MA 01757
Hamilton Jordan director
Stuart C Mcwhorter director 113 SEABOARD LANE, FRANKLIN TN 37067
Timothy J Barberich director 40 ELM ST, CONCORD MA 01752
Michael P Duffy officer: SVP, GC and Secretary C/O POINT THERAPEUTICS INC, 125 SUMMER STREET SUITE 1840, BOSTON MA 02110
Richard J Benjamin director 15 WHITE PINE ROAD, NEWTON MA 02464
Larry G Pickering director 26130 MANDEVILLA DRIVE, BONITA SPRINGS FL 34134

DARA Biosciences (DARA Biosciences) Headlines